Can we predict mucosal remission in ulcerative colitis more precisely with a redefined cutoff level of C-reactive protein?

被引:8
作者
Bakkaloglu, Oguz Kagan [1 ]
Eskazan, Tugce [1 ]
Celik, Sinem [2 ]
Kurt, Enes Ali [1 ]
Hatemi, Ibrahim [1 ]
Erzin, Yusuf [1 ]
Celik, Aykut Ferhat [1 ]
机构
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Internal Med, Sect Gastroenterol, Istanbul, Turkey
[2] Acibadem Univ, Atasehir Acibadem Hosp, Istanbul, Turkey
关键词
CRP; endoscopic remission; mucosal remission; ulcerative colitis; FECAL CALPROTECTIN; CROHNS-DISEASE; ENDOSCOPIC ACTIVITY; CRP;
D O I
10.1111/codi.15940
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim Most patients with ulcerative colitis (UC) with active mucosal disease have a lower C-reactive protein (CRP) level than the classic accepted cutoff level (<= 5 mg/l). We aimed to predict the mucosal remission in UC with an optimal cutoff level of CRP when mucosal activity and extensiveness of UC were both considered. Method In this retrospective study, we evaluated CRP values and their relation to mucosal extension and UC activity in 331 colonoscopic examinations performed between December 2016 and March 2019. Endoscopic activity and disease extension were assessed using Mayo scores and the Montreal classification. Results The Mayo 2 and 3 groups' CRP values were significantly higher when compared with Mayo 0-1 between values of E1 and both E2 and E3 with an increasing trend. The standard CRP cutoff level <= 5 mg/l only yielded 55% specificity in predicting mucosal remission. In the ROC analysis, a CRP cutoff level <= 2.9 mg/l predicted an overall mucosal remission (Mayo 0-1) with 77% sensitivity and 80% specificity, and <= 1.9 mg/l predicted Mayo-0 with 70% sensitivity and specificity. In the clinical remission subgroup, the overall CRP cutoff level was even lower, at <= 1.58 mg/l. Conclusion An overall CRP cutoff level <= 2.9 mg/l predicts mucosal remission in UC better than the standard cutoff <= 5 mg/l. Mucosal remission in stable clinical remission may present with an even lower CRP level. An increasing trend in the CRP level from E1 through E3 even in mucosal remission suggests that both histological inflammation and extensiveness may have some influence on a CRP-based prediction of endoscopic remission.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 20 条
[1]   Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels [J].
Carlson, CS ;
Aldred, SF ;
Lee, PK ;
Tracy, RP ;
Schwartz, SM ;
Rieder, M ;
Liu, KA ;
Williams, OD ;
Iribarren, C ;
Lewis, EC ;
Fornage, M ;
Boerwinkle, E ;
Gross, M ;
Jaquish, C ;
Nickerson, DA ;
Myers, RM ;
Siscovick, DS ;
Reiner, AP .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (01) :64-77
[2]   Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease [J].
D'Haens, Geert ;
Ferrante, Marc ;
Vermeire, Severine ;
Baert, Filip ;
Noman, Maja ;
Moortgat, Liesbeth ;
Geens, Patricia ;
Iwens, Doreen ;
Aerden, Isolde ;
Van Assche, Gert ;
Van Olmen, Gust ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) :2218-2224
[3]   SERUM LEVELS OF C-REACTIVE PROTEIN IN CROHNS-DISEASE AND ULCERATIVE-COLITIS [J].
FAGAN, EA ;
DYCK, RF ;
MATON, PN ;
HODGSON, HJF ;
CHADWICK, VS ;
PETRIE, A ;
PEPYS, MB .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1982, 12 (04) :351-359
[4]   Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis [J].
Ippolito, Chiara ;
Colucci, Rocchina ;
Segnani, Cristina ;
Errede, Mariella ;
Girolamo, Francesco ;
Virgintino, Daniela ;
Dolfi, Amelio ;
Tirotta, Erika ;
Buccianti, Piero ;
Di Candio, Giulio ;
Campani, Daniela ;
Castagna, Maura ;
Bassotti, Gabrio ;
Villanacci, Vincenzo ;
Blandizzi, Corrado ;
Bernardini, Nunzia .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (10) :1194-1204
[5]   Systematic Review with Meta-Analysis: Fecal Calprotectin as a Surrogate Marker for Predicting Relapse in Adults with Ulcerative Colitis [J].
Li, Jiajia ;
Zhao, Xiaojing ;
Li, Xueting ;
Lu, Meijiao ;
Zhang, Hongjie .
MEDIATORS OF INFLAMMATION, 2019, 2019
[6]   C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis [J].
Mosli, Mahmoud H. ;
Zou, Guangyong ;
Garg, Sushil K. ;
Feagan, Sean G. ;
MacDonald, John K. ;
Chande, Nilesh ;
Sandborn, William J. ;
Feagan, Brian G. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (06) :802-819
[7]   Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis [J].
Patel, Anish ;
Panchal, Hinaben ;
Dubinsky, Marla C. .
INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) :1600-1604
[8]   A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders [J].
Poullis, AP ;
Zar, S ;
Sundaram, KK ;
Moodie, SJ ;
Risley, P ;
Theodossi, A ;
Mendall, MA .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (04) :409-412
[9]   Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease [J].
Safroneeva, E. ;
Vavricka, S. R. ;
Fournier, N. ;
Pittet, V. ;
Peyrin-Biroulet, L. ;
Straumann, A. ;
Rogler, G. ;
Schoepfer, A. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (08) :977-989
[10]   DIFFERING ACUTE PHASE RESPONSES IN CROHNS-DISEASE AND ULCERATIVE-COLITIS [J].
SAVERYMUTTU, SH ;
HODGSON, HJF ;
CHADWICK, VS ;
PEPYS, MB .
GUT, 1986, 27 (07) :809-813